These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22280363)

  • 1. Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.
    Baud MG; Leiser T; Haus P; Samlal S; Wong AC; Wood RJ; Petrucci V; Gunaratnam M; Hughes SM; Buluwela L; Turlais F; Neidle S; Meyer-Almes FJ; White AJ; Fuchter MJ
    J Med Chem; 2012 Feb; 55(4):1731-50. PubMed ID: 22280363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic profiling of the antitumor natural product psammaplin A and its analogues.
    García J; Franci G; Pereira R; Benedetti R; Nebbioso A; Rodríguez-Barrios F; Gronemeyer H; Altucci L; de Lera AR
    Bioorg Med Chem; 2011 Jun; 19(12):3637-49. PubMed ID: 21215647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, biological evaluation and molecular modeling studies of psammaplin A and its analogs as potent histone deacetylases inhibitors and cytotoxic agents.
    Wen J; Bao Y; Niu Q; Liu J; Yang J; Wang W; Jiang T; Fan Y; Li K; Wang J; Zhao L; Liu D
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4372-6. PubMed ID: 27460171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psammaplin A is a natural prodrug that inhibits class I histone deacetylase.
    Kim DH; Shin J; Kwon HJ
    Exp Mol Med; 2007 Feb; 39(1):47-55. PubMed ID: 17334228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient synthesis and biological activity of Psammaplin A and its analogues as antitumor agents.
    Hong S; Shin Y; Jung M; Ha MW; Park Y; Lee YJ; Shin J; Oh KB; Lee SK; Park HG
    Eur J Med Chem; 2015; 96():218-30. PubMed ID: 25884112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psammaplin A analogues with modified disulfide bond targeting histone deacetylases: Synthesis and biological evaluation.
    Jiang Y; Tang Y; Li Y; Liu L; Yue K; Li X; Qiu P; Yin R; Jiang T
    Eur J Med Chem; 2024 Sep; 275():116541. PubMed ID: 38851056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
    Cincinelli R; Musso L; Artali R; Guglielmi M; Bianchino E; Cardile F; Colelli F; Pisano C; Dallavalle S
    Eur J Med Chem; 2018 Jan; 143():2005-2014. PubMed ID: 29150335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly ligand efficient and selective N-2-(Thioethyl)picolinamide histone deacetylase inhibitors inspired by the natural product psammaplin A.
    Baud MG; Haus P; Leiser T; Meyer-Almes FJ; Fuchter MJ
    ChemMedChem; 2013 Jan; 8(1):149-56. PubMed ID: 23184734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New synthetic strategies towards psammaplin A, access to natural product analogues for biological evaluation.
    Baud MG; Leiser T; Meyer-Almes FJ; Fuchter MJ
    Org Biomol Chem; 2011 Feb; 9(3):659-62. PubMed ID: 21113514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
    Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescent analogs of the marine natural product psammaplin A: synthesis and biological activity.
    Hentschel F; Sasse F; Lindel T
    Org Biomol Chem; 2012 Sep; 10(35):7120-33. PubMed ID: 22872318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indole-derived psammaplin A analogues as epigenetic modulators with multiple inhibitory activities.
    Pereira R; Benedetti R; Pérez-Rodríguez S; Nebbioso A; García-Rodríguez J; Carafa V; Stuhldreier M; Conte M; Rodríguez-Barrios F; Stunnenberg HG; Gronemeyer H; Altucci L; de Lera AR
    J Med Chem; 2012 Nov; 55(22):9467-91. PubMed ID: 23030799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy.
    Yuan Z; Chen S; Gao C; Dai Q; Zhang C; Sun Q; Lin JS; Guo C; Chen Y; Jiang Y
    Bioorg Chem; 2019 Jun; 87():200-208. PubMed ID: 30901675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.
    Wen J; Bao Y; Niu Q; Yang J; Fan Y; Li J; Jing Y; Zhao L; Liu D
    Eur J Med Chem; 2016 Feb; 109():350-9. PubMed ID: 26814680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
    Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
    J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
    Tang G; Wong JC; Zhang W; Wang Z; Zhang N; Peng Z; Zhang Z; Rong Y; Li S; Zhang M; Yu L; Feng T; Zhang X; Wu X; Wu JZ; Chen L
    J Med Chem; 2014 Oct; 57(19):8026-34. PubMed ID: 25238284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An improved synthesis of psammaplin A.
    Godert AM; Angelino N; Woloszynska-Read A; Morey SR; James SR; Karpf AR; Sufrin JR
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3330-3. PubMed ID: 16632351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
    Krieger V; Hamacher A; Gertzen CGW; Senger J; Zwinderman MRH; Marek M; Romier C; Dekker FJ; Kurz T; Jung M; Gohlke H; Kassack MU; Hansen FK
    J Med Chem; 2017 Jul; 60(13):5493-5506. PubMed ID: 28574690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.